The addition of testosterone therapy improves erectile function in hypogonadal men who fail to respond to phosphodiesterase type 5 inhibitor (PDE5-I) therapy alone

Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). Buvat J, Montorsi F, Maggi M, et al. J Sex Med 2011;8(1):284-293.

May 20th, 2011

This study aimed to confirm that testosterone replacement therapy (Testogel®, Androgel®) improved erectile function in men with erectile dysfunction (ED) who were nonresponders to phosphodiesterase type 5 inhibitors (PDE5-Is). The study also investigated the impact of baseline testosterone levels on response to treatment. The multicentre, multinational, double-blind, placebo-controlled study (TADTEST) included 173 men (age 45–80 years) with baseline total testosterone levels ≤400 ng/dL or bioavailable testosterone ≤100 ng/dL and inadequate response to 4 weeks of treatment with the PDE5-I tadalafil (Cialis®) 10 mg once a day. Once-daily tadalafil treatment was continued for an additional 12 weeks and men were randomized also to receive placebo or testosterone 50 mg once daily in the form of a 1% hydro-alcoholic gel, to be increased to 100 mg if results were unsatisfactory. The Erectile Function Domain (EFD) Score of the International Index of Erectile Function (IIEF) and rate of successful intercourse attempts were the main outcomes measured.1

Key Points

  • The mean baseline total serum testosterone level in the overall population was 337.0 ± 148 ng/dL (11.7 ± 6.0 nmol/L)1
  • Mean baseline level of bioavailable testosterone was 73.0 ± 21.0 ng/dL (2.5 ± 0.7 nmol/L)1
  • Total and bioavailable testosterone levels increased significantly following administration of the testosterone gel1
  • Erectile function progressively improved in both the placebo and testosterone gel groups during ≥12 weeks of follow-up1
  • Testosterone gel was significantly superior to placebo in improving the EFD score of the IIEF in men with a baseline testosterone level ≤300 ng/dL (10.4 nmol/L)1, a widely accepted definition of hypogonadism2
  • In these men, EFD score increased by 6.18 points in the testosterone group after 8 weeks of combination therapy, compared with 2.33 points in the placebo group (p<0.027) (Figure 1)1
  • The increase in successful intercourse rate increased correspondingly by 33.1% vs 13.4% (p<0.038) (Figure 1)1
  • The lower the baseline level of testosterone, the lower the improvement in sexual function obtained by tadalafil alone in the placebo group1
  • Hypogonadal men with baseline testosterone levels ≤300 ng/dL may benefit from the addition of testosterone replacement therapy to optimal ED therapy with tadalafil.1

What is known

Failure to respond to treatment with PDE5-Is occurs in approximately a third of men with ED.1 As the pharmacological activity of PDE5-Is appears from animal studies3-5 and in humans6 to be androgen-dependent, non-response to PDE5-Is may be explained at least in part by testosterone deficiency. Furthermore, testosterone deficiency has been shown to predict a poor response to PDE5-Is,7-13and the addition of testosterone replacement therapy to a PDE5-I appears from non-comparative studies to improve erectile function in men with low testosterone.7-10,12

However, data from randomised, placebo-controlled trials have been limited. This multicentre controlled study was designed to test whether the action of PDE5-Is in men is androgen-dependent and to investigate whether a threshold value exists for the additive effect of testosterone on PDE5-I therapy.

What this study adds

This study provides supporting evidence that ED patients with low testosterone levels (≤300 ng/dL [10.4 nmol/L] total testosterone) treated with a PDE5-I benefit from the addition of testosterone replacement therapy. It should be noted that a once-daily dosage of tadalafil 10 mg was used in this study, which is the recommended starting dose of tadalafil for use as needed in most patients, and is higher than the 5 mg dose approved for once-daily administration since the study was designed. Nevertheless, the study shows that testosterone replacement therapy (in this case testosterone gel) is beneficial in improving the response of ED therapy in men with hypogonadism.

For detailed information you should directly visit here


About yuan ade sukma, MD

I'm an Indonesian doctor. I Believe that science and knowledge do not belong to anyone in the world. Science and knowledge is meant to be shared to make the world a better place to live. But if you find any material posted here is violating any copyrights, feel free to contact me and I will delete that. I believe that someday my blog can change the world. I BELIEVE in the POWER of WORDS! Do you..?
Gallery | This entry was posted in Andrology Latest Update and tagged , , . Bookmark the permalink.

4 Responses to The addition of testosterone therapy improves erectile function in hypogonadal men who fail to respond to phosphodiesterase type 5 inhibitor (PDE5-I) therapy alone

  1. I’d forever want to be update on new posts on this internet site , bookmarked ! .

  2. Hormone replacement therapies are all consider to be dangerous but now it is more safe than past but testosterone therapy may also help in other diseases.

  3. Thanks a lot for sharing such a wonderful information regarding the testosterone therapy which help a lot in the So thanks a lot once again. It will be very helpful to me because I am suffering a lot from erectile dysfunction. So Thank You.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s